Gerber Kawasaki Wealth & Investment Management Has $3.22 Million Stock Holdings in Invesco Biotechnology & Genome ETF $PBE

Gerber Kawasaki Wealth & Investment Management decreased its stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 81.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 46,137 shares of the company’s stock after selling 208,035 shares during the period. Gerber Kawasaki Wealth & Investment Management owned 1.47% of Invesco Biotechnology & Genome ETF worth $3,224,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of PBE. Royal Bank of Canada raised its holdings in Invesco Biotechnology & Genome ETF by 22.3% in the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after acquiring an additional 13,767 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Invesco Biotechnology & Genome ETF by 5.9% in the first quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock valued at $2,389,000 after purchasing an additional 2,103 shares during the last quarter. Allworth Financial LP acquired a new position in shares of Invesco Biotechnology & Genome ETF in the second quarter valued at approximately $54,000. Osaic Holdings Inc. increased its stake in shares of Invesco Biotechnology & Genome ETF by 9.9% during the second quarter. Osaic Holdings Inc. now owns 9,441 shares of the company’s stock worth $605,000 after purchasing an additional 852 shares during the period. Finally, Sowell Financial Services LLC bought a new position in shares of Invesco Biotechnology & Genome ETF during the third quarter worth approximately $208,000.

Invesco Biotechnology & Genome ETF Trading Down 1.3%

NYSEARCA:PBE opened at $77.78 on Monday. The stock has a 50 day simple moving average of $82.17 and a 200 day simple moving average of $77.44. The stock has a market cap of $249.67 million, a P/E ratio of 20.44 and a beta of 0.79. Invesco Biotechnology & Genome ETF has a 1-year low of $54.52 and a 1-year high of $85.73.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.